Novo Nordisk Prices 7.2mg Wegovy HD at $399, Undercutting Lilly by 40%
Novo Nordisk will launch a 7.2mg Wegovy HD injection priced at $399 per month, roughly 40% below Lilly’s Zepbound top-tier doses. The new formulation and lower price aim to close efficacy and accessibility gaps as the obesity drug market intensifies competition.
1. Launch of Wegovy HD
Novo Nordisk has introduced Wegovy HD, a 7.2mg injectable dose priced at $399 per month for cash-pay patients. This represents a threefold increase over its previous top dose and a significant 40% discount versus the highest Zepbound price tier.
2. Competitive positioning
The higher-strength formulation is designed to narrow the efficacy gap highlighted by Lilly’s Zepbound trial results. By combining dose escalation with aggressive pricing, Novo aims to regain momentum in the $190 billion obesity treatment market.
3. Distribution strategy
Wegovy HD will be available through NovoCare, traditional pharmacies and select telehealth partners. Existing subscription programs may incorporate the new dose at standard rates, offering flexible access and pricing structures to drive patient uptake.